Literature DB >> 1095022

Selective suppression of autoantibody responses in NZB/NZW mice treated with long-term cyclophosphamide.

S E Walker, G G Bole.   

Abstract

Autoimmune responses were assayed in 80 cyclophosphamide-treated and control NZB/NZW mice over a period of 1 year. Fluctuation between positive and negative immunofluorescent heterogeneous ANA tests and daily alterations of ANA titers were detected in young mice of both sexes. Although high-dose cyclophosphamide therapy (8 mg/kg/day) failed to prevent the spontaneous appearance of ANA, titered ANA values were partially suppressed in high-dose treated mice. This study permitted sequential comparisons between ANA titers and anti-DNA as useful indices of cyclophosphamide-induced suppression of autoimmune disease. ANA titers were relatively resistant to cyclophosphamide therapy. Antibodies directed specifically against DNA were suppressed mice receiving high-dose cyclophosphamide. In treated animals, decreased anti-DNA levels were associated with protection from severe glomerulonephritis and renal vasculitis. Treatment with low-dose cyclophosphamide (1 mg/kg/day) appeared paradoxically to stimulate autoantibody production and renal disease/vasculitis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1095022     DOI: 10.1002/art.1780180312

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

1.  Increased survival times of New Zealand hybrid mice immunosuppressed by graft-versus-host reactions.

Authors:  D H Lehman; C B Wilson; F J Dixon
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

2.  Therapeutic effect of beta-[1-phenyl-5-bis(beta-chloroethyl)-amino-benzimidazolyl-(2)-DL-alanin (ZIMET 3164) on immune complex nephritis of NZB hybrid mice.

Authors:  J Güttner
Journal:  Agents Actions       Date:  1979-12

Review 3.  The NZB/W F1 mouse model for Sjögren's syndrome: A historical perspective and lessons learned.

Authors:  Harini Bagavant; Aleksandra Michrowska; Umesh S Deshmukh
Journal:  Autoimmun Rev       Date:  2020-10-22       Impact factor: 9.754

4.  Relation of titred peripheral pattern ANA to anti-DNA and disease activity in systemic lupus erythematosus.

Authors:  R J Weitzman; S E Walker
Journal:  Ann Rheum Dis       Date:  1977-02       Impact factor: 19.103

5.  Levamisole maintains cyclophsophamide-induced remission in murine lupus erythematosus.

Authors:  J Zulman; J Michalski; C McCombs; J Greenspan; N Talal
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

6.  The effect of chronic daily cyclophosphamide administration on established antibody responses.

Authors:  R F Gagnon; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

7.  Suppressed hetergeneous antinuclear antibody response in lymphomabearing NZB/NZW mice.

Authors:  S E Walker; G G Bole
Journal:  Clin Exp Immunol       Date:  1976-04       Impact factor: 4.330

8.  Successful treatment of autoimmune disease in (NZB/NZW)F1 female mice by using fractionated total lymphoid irradiation.

Authors:  S Slavin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

9.  Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone.

Authors:  S E Walker; M R Anver
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

10.  Tissue graft rejection in murine models of autoimmune disease.

Authors:  J Schultz; R Demott-Friberg; S Walker; T F Beals
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.